Tarsus Pharmaceuticals, Inc. Announces That XDEMVY 0.25% Is Now Available At Pharmacies Nationwide For Prescription. The U.S. FDA Approved Drug On July 24, 2023, For The Treatment Of Demodex Blepharitis
Portfolio Pulse from Happy Mohamed
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has announced that its FDA-approved drug, XDEMVY 0.25%, is now available at pharmacies nationwide for prescription. The drug is used for the treatment of Demodex blepharitis, a condition that affects approximately 25 million eye care patients in the U.S. Tarsus has also developed Tarsus Connect, a suite of assistance programs that provide financial support for eligible patients.
August 24, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tarsus Pharmaceuticals' drug, XDEMVY, is now available for prescription nationwide. This could potentially increase the company's revenues as the drug is used to treat a condition that affects 25 million patients in the U.S.
The availability of XDEMVY nationwide could potentially increase Tarsus' revenues as the drug is used to treat a condition that affects a significant number of patients in the U.S. Furthermore, the company's commitment to ensuring affordable access to the drug through Tarsus Connect could also boost its sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100